Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADAM metallopeptidase domain 29 (ADAM29) is a membrane-anchored protein and a member of the ADAM (A Disintegrin And Metalloproteinase) family, structurally related to snake venom disintegrins. While all ADAMs contain a metalloproteinase domain, ADAM29 appears to be catalytically inactive (i.e., it is a non-catalytic metalloprotease-like protein) due to mutations in the active site, suggesting its biological role is primarily via protein-protein interactions rather than enzymatic proteolysis. It is highly expressed in the testis and may play a role in spermatogenesis and fertilization by facilitating cell-cell or cell-matrix interactions required in these processes. Dysregulation of ADAM29 has been linked to diseases such as melanoma, but, unlike better studied ADAM family members, there are currently no drugs or specific mechanisms of action reported for it, nor is it established as a clinical biomarker or safety concern.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ADAM metallopeptidase domain 29 (ADAM29).